<DOC>
	<DOCNO>NCT00905996</DOCNO>
	<brief_summary>In patient never bleed gastric varix ( GOV2 IGV1 ) , cyanoacrylate injection well beta-blocker therapy treatment prevention gastric variceal bleed . The investigator conduct randomize controlled trial patient gastric varix ( GOV2 IGV1 ) never bleed , study efficacy treatment cyanoacrylate injection versus beta-blocker versus treatment prevention first bleed gastric varix .</brief_summary>
	<brief_title>Primary Prophylaxis Gastric Varix Bleed</brief_title>
	<detailed_description>Patients follow every 3 month time end point complication .</detailed_description>
	<mesh_term>Adrenergic beta-Antagonists</mesh_term>
	<mesh_term>Propranolol</mesh_term>
	<criteria>Patients GOV2 eradicate esophageal varix IGV1 , never bleed gastric varix include . Only esophageal varix , GOV1 GOV2 , acute bleed past history bleed gastric varix , contraindication betablocker therapy cyanoacrylate injection . Prior injection cyanoacrylate sclerotherapy variceal ligation transjugular intrahepatic portosystemic shunt balloonoccluded retrograde transvenous obliteration balloonoccluded endoscopic injection sclerotherapy gastric varix prevention bleed GV Patients already betablocker nitrate Undetermined origin bleed esophageal varix gastric varix Hepatic encephalopathy grade III/IV Hepatorenal syndrome Hepatocellular carcinoma Presence deep jaundice ( serum bilirubin &gt; 10 mg/dl ) Uremia Cerebrovascular accident Cardiorespiratory failure Pregnancy patient give informed consent endoscopic procedure</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2009</verification_date>
</DOC>